查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1391954

肿瘤微环境市场：按癌症类型、标靶、治疗方法、最终用户和地区分类

Tumor Microenvironment Market, By Cancer Type, Target, Therapy (Monoclonal Antibodies, Cytokines, Cancer Vaccines, Oncolytic Viruses, Adoptive Cell Therapies & Others), End User (Biopharmaceutical Companies, Hospitals, & Others), Geography
出版日期: | 出版商: Coherent Market Insights | 英文 160 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2023年全球肿瘤微环境市场规模为14.7亿美元，预计2030年将达34.3亿美元，2023-2030年复合年增长率为12.9%。

报告范围 报告详情
基准年 2022年 2023年市场规模 14.7亿美元
实绩资料 2018-2021 预测期 2023-2030
预测期复合年增长率 12.90% 2030年市场规模预测 34.3亿美元
图 1. 2023 年全球肿瘤微环境市场占有率(%)（按地区）
肿瘤微环境市场-IMG1

肿瘤微环境是一个复杂的生态系统，由各种细胞和非细胞成分组成，它们相互作用，在肿瘤的发生和进展中发挥重要作用。这些成分包括免疫细胞、纤维母细胞、血管、细胞外基质和讯号分子。了解肿瘤微环境对于开发有效治疗癌症的标靶治疗至关重要。近年来，随着我们认识到癌细胞与其周围环境之间动态相互作用的重要性，肿瘤微环境的研究引起了广泛的关注。现在已经清楚，肿瘤微环境影响血管生成、免疫反应、转移和抗药性等多种过程。

市场动态：

由于多种因素，肿瘤微环境市场预计在未来几年将显着成长。主要因素之一是全世界癌症发生率的增加。根据世界卫生组织 (WHO) 2020 年的数据，癌症是全球主要死亡原因之一，每年报告约 1,000 万新患者和 600 万人死亡。这增加了对了解和治疗癌症的先进方法的需求，从而推动了市场成长。

然而，高昂的研发成本、严格的监管要求以及在肿瘤微环境研究中使用动物模型的伦理问题等因素可能会抑制市场成长。此外，熟练专家的有限和调查方法缺乏标准化也可能对市场成长构成挑战。

儘管有这些挑战，肿瘤微环境市场仍存在巨大的成长机会。多光子显微镜和活体成像等成像技术的进步使研究人员能够即时、高解析度地研究肿瘤微环境。此外，个人化医疗的出现和对精准肿瘤学的日益关注创造了对能够洞察肿瘤微环境的生物标记的需求，进一步推动市场成长。

此外，市场参与企业正在采取联盟等无机策略，预计这将在预测期内促进全球肿瘤微环境市场的成长。例如，2023年3月20日，德国生物技术公司BioNTech SE与临床阶段生物製药公司OncoC4, Inc.宣布，OncoC4的下一代抗CTLA-4单株抗体候选物ONC-392宣布已达成合作协议。全球独家许可和合作协议，用于开发和商业化该药物作为多种癌症适应症的单一疗法或联合治疗。 CTLA-4是一种透过多种机制抑制免疫细胞活性的分子。 OncoC4 的 CTLA-4 候选抗体 ONC-392 旨在消除肿瘤微环境中的免疫抑制 T 细胞（调节性 T 细胞，「Treg」）并保留健康组织中的 Tregs。

本研究的主要特点

  • 本报告详细分析了全球肿瘤微环境市场，并提供了以2022年为基准年的预测期（2023-2030）的市场规模和年复合成长率（CAGR%）。
  • 它还揭示了各个细分市场的潜在商机，并为该市场说明了一系列有吸引力的投资提案。
  • 它还提供了有关市场驱动因素、抑制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的主要考察。
  • 它根据公司亮点、产品系列、主要亮点、财务实绩和策略等参数，介绍了全球肿瘤微环境市场的主要企业。
  • 该报告的见解使行销人员和公司负责人能够就未来的产品发布、升级、市场扩张和行销策略做出资讯的决策。
  • 全球肿瘤微环境市场报告针对该行业的各个相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
  • 透过用于分析全球肿瘤微环境市场的各种策略矩阵，将有助于相关人员做出决策。

目录

第一章 研究目的与假设

  • 研究目标
  • 假设
  • 简称

第二章 市场展望

  • 报告说明
    • 市场定义和范围
  • 执行摘要
  • Coherent Opportunity Map（COM）

第三章市场动态、法规及趋势分析

  • 市场动态
    • 癌症发生率增加
    • 与试剂相关的高成本
    • 介绍人工智慧和机器学习
  • 影响分析
  • 主要亮点
  • 监管场景
  • 产品发布/核准
  • PEST分析
  • 波特的分析
  • 併购场景

第四章肿瘤微环境市场－冠状病毒（COVID-19）大流行的影响

  • 新型冠状病毒感染疾病（COVID-19）的流行病学
  • 供需面分析
  • 经济影响

第五章肿瘤微环境市场，依癌症类型，2018-2030

  • 介绍
  • 肺癌
  • 大肠直肠癌
  • 乳癌
  • 摄护腺癌
  • 膀胱癌
  • 其他（黑色素瘤、肾臟癌、卵巢癌等）

第六章肿瘤微环境市场，依目标，2018-2030

  • 介绍
  • T细胞
  • 肿瘤相关巨噬细胞
  • 骨髓源性抑制细胞
  • 癌症相关纤维母细胞
  • 调节性T细胞
  • 其他（肿瘤相关嗜中性白血球、树突状细胞等）

第七章肿瘤微环境市场，依治疗方法，2018-2030

  • 介绍
  • 单株抗体
  • 细胞因子
  • 癌症疫苗
  • 溶瘤病毒
  • 过继性细胞疗法
  • 其他（基因治疗、免疫调节剂、检查点抑制剂等）

第 8 章肿瘤微环境市场，依最终使用者划分，2018-2030 年

  • 介绍
  • 生物製药公司
  • 医院
  • 诊断实验室
  • 研究机构
  • 受託研究机构（CRO）
  • 其他（学术机构等）

第9章肿瘤微环境市场，依地区，2018-2030

  • 介绍
  • 北美洲
  • 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲
  • 欧洲
  • 德国
  • 英国
  • 西班牙
  • 法国
  • 义大利
  • 俄罗斯
  • 欧洲其他地区
  • 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • 东南亚国协
  • 其他亚太地区
  • 中东和非洲
  • 海湾合作委员会国家
  • 以色列
  • 南非
  • 北非
  • 中部非洲
  • 其他中东地区

第10章竞争形势

  • Thermo Fisher Scientific
  • Illumina
  • Danaher Corporation
  • Merck KGaA
  • BD Biosciences
  • Promega Corporation
  • Bio-Techne Corporation
  • Bio-Rad Laboratories
  • F.Hoffmann-La Roche Ltd
  • QIAGEN NV
  • Sartorius AG
  • PerkinElmer
  • Miltenyi Biotec
  • Cell Signaling Technology
  • BioLegend
  • Abcam
  • Takara Bio
  • Fluidigm Corporation
  • NanoString Technologies
  • 10x Genomics
  • Bethyl Laboratories

第11章 章节

  • 调查方法
  • 关于出版商
简介目录
Product Code: CMI6238

The global tumor microenvironment market size was valued at US$ 1.47 Bn in 2023 and is expected to reach US$ 3.43 Bn by 2030, grow at a compound annual growth rate (CAGR) of 12.9% from 2023 to 2030.

Report Coverage Report Details
Base Year: 2022 Market Size in 2023: US$ 1.47 Bn
Historical Data for: 2018 to 2021 Forecast Period: 2023 - 2030
Forecast Period 2023 to 2030 CAGR: 12.90% 2030 Value Projection: US$ 3.43 Bn
Figure 1. Global Tumor Microenvironment Market Share (%), By Region, 2023
Tumor Microenvironment Market - IMG1

The tumor microenvironment is a complex ecosystem consisting of various cellular and non-cellular components that interact with each other and play a crucial role in tumor development and progression. These components include immune cells, fibroblasts, blood vessels, the extracellular matrix, and signaling molecules. Understanding the tumor microenvironment is essential for developing targeted therapies that can effectively treat cancer. The study of the tumor microenvironment has gained significant attention in recent years, as researchers have realized the importance of this dynamic interaction between tumor cells and their surroundings. It is now evident that the tumor microenvironment can influence various processes, such as angiogenesis, immune response, metastasis, and drug resistance.

Market Dynamics:

The tumor microenvironment market is expected to witness significant growth in the coming years, driven by several factors. One of the major drivers is the increasing incidence of cancer worldwide. According to the World Health Organization (WHO), 2020, cancer is one of the leading causes of death globally, with approximately 10 million new cases and 6 million deaths reported annually. This has led to a substantial demand for advanced methods to understand and treat cancer, thereby driving market growth.

However, market growth can be restrained by factors, such as the high cost of research and development, stringent regulatory requirements, and ethical concerns related to the use of animal models in tumor microenvironment studies. Additionally, the limited availability of skilled professionals and the lack of standardization in research methodologies can pose challenges to market growth.

Despite these challenges, the tumor microenvironment market offers significant opportunities for growth. Technological advancements in imaging techniques, such as multiphoton microscopy and intravital imaging, have enabled researchers to study the tumor microenvironment in real-time and high resolution. Moreover, the emergence of personalized medicine and the increasing focus on precision oncology have created a demand for biomarkers that can provide insights into the tumor microenvironment, further driving market growth.

Moreover, market players are engaged in conducting inorganic strategies such as collaborations, and this is expected to increase the growth of the global tumor microenvironment market over the forecast period. For instance, on March 20, 2023, BioNTech SE, a German biotechnology company and OncoC4, Inc., a clinical-stage biopharmaceutical company, announced that they had entered into an exclusive worldwide license and collaboration agreement to develop and commercialize OncoC4's next-generation anti-CTLA-4 monoclonal antibody candidate, ONC-392, as monotherapy or combination therapy in various cancer indications. CTLA-4 is a molecule that inhibits the activity of immune cells via various mechanisms. OncoC4's CTLA-4 antibody candidate, ONC-392, aims to delete immunosuppressive T cells (regulatory T cells, "Tregs") in the tumor microenvironment but spare Tregs in healthy tissues.

Key features of the study:

  • This report provides in-depth analysis of the global tumor microenvironment market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global tumor microenvironment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Thermo Fisher Scientific, Illumina, Danaher Corporation, Merck KGaA , BD Biosciences, Promega Corporation, Bio-Techne Corporation , Bio-Rad Laboratories, F. Hoffmann-La Roche Ltd, QIAGEN N.V., Sartorius AG, PerkinElmer, Miltenyi Biotec, Cell Signaling Technology, BioLegend, Abcam, Takara Bio, Fluidigm Corporation, NanoString Technologies, 10x Genomics, and Bethyl Laboratories
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global tumor microenvironment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global tumor microenvironment market

Detailed Segmentation:

  • By Cancer Type
    • Lung Cancer
    • Colorectal Cancer
    • Breast Cancer
    • Prostate Cancer
    • Bladder Cancer
    • Others (Melanoma, Kidney cancer, Ovarian cancer etc.)
  • By Target
    • T Cells
    • Tumor-Associated Macrophages
    • Myeloid-Derived Suppressor Cells
    • Cancer-Associated Fibroblasts
    • Regulatory T Cells
    • Others (Tumor-associated neutrophils, Dendritic cells etc.)
  • By Therapy:
    • Monoclonal Antibodies
    • Cytokines
    • Cancer Vaccines
    • Oncolytic Viruses
    • Adoptive Cell Therapies
    • Others (Gene therapies, Immunomodulators,Checkpoint inhibitors etc.)
  • By End User
    • Biopharmaceutical Companies
    • Hospitals
    • Diagnostic Laboratories
    • Research Institutes
    • Contract Research Organizations (CROs)
    • Others (Academic Institutes and Others)
  • By Region
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East & Africa
  • Key Players
    • Thermo Fisher Scientific
    • Illumina
    • Danaher Corporation
    • Merck KGaA
    • BD Biosciences
    • Promega Corporation
    • Bio-Techne Corporation
    • Bio-Rad Laboratories
    • F.Hoffmann-La Roche Ltd
    • QIAGEN N.V.
    • Sartorius AG
    • PerkinElmer
    • Miltenyi Biotec
    • Cell Signaling Technology
    • BioLegend
    • Abcam
    • Takara Bio
    • Fluidigm Corporation
    • NanoString Technologies
    • 10x Genomics
    • Bethyl Laboratories

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Tumor Microenvironment, By Cancer Type
    • Market Tumor Microenvironment, By Target
    • Market Tumor Microenvironment, By Therapy
    • Market Tumor Microenvironment, By End User
    • Market Tumor Microenvironment, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Increasing cancer prevalence
    • High costs associated with reagents
    • Adoption of AI and machine learning
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product launch/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Tumor Microenvironment Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Tumor Microenvironment Market , By Cancer Type, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Lung Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Colorectal Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Breast Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Prostate Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Bladder Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Others (Melanoma, Kidney cancer, Ovarian cancer etc.)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

6. Tumor Microenvironment Market , By Target, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018 - 2030
    • Segment Trends
  • T Cells
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Tumor-associated Macrophages
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Myeloid-Derived Suppressor Cells
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Cancer-Associated Fibroblasts
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Regulatory T Cells
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Others (Tumor-associated neutrophils, Dendritic cells etc.)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

7. Tumor Microenvironment Market , By Therapy, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018 - 2030
    • Segment Trends
  • Monoclonal Antibodies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Cytokines
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Cancer Vaccines
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Oncolytic Viruses
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Adoptive Cell Therapies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Others (Gene therapies, Immunomodulators,Checkpoint inhibitors etc.)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

8. Tumor Microenvironment Market , By End User, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018 - 2030
    • Segment Trends
  • Biopharmaceutical Companies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Hospitals
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Diagnostic Laboratories
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Research Institutes
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Contract Research Organizations (CROs)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Others (Academic Institutes and Others)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

9. Tumor Microenvironment Market , By Region, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, By Country, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, For Country 2018 -2030
    • Country Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
    • U.S.
    • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East & Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
  • GCC Countries
  • Israel
  • South Africa
  • North Africa
  • Central Africa
  • Rest of Middle East

10. Competitive Landscape

  • Thermo Fisher Scientific
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Illumina
  • Danaher Corporation
  • Merck KGaA
  • BD Biosciences
  • Promega Corporation
  • Bio-Techne Corporation
  • Bio-Rad Laboratories
  • F.Hoffmann-La Roche Ltd
  • QIAGEN N.V.
  • Sartorius AG
  • PerkinElmer
  • Miltenyi Biotec
  • Cell Signaling Technology
  • BioLegend
  • Abcam
  • Takara Bio
  • Fluidigm Corporation
  • NanoString Technologies
  • 10x Genomics
  • Bethyl Laboratories
  • Analyst Views

11. Section

  • Research Methodology
  • About us